Key terms
About OCUL
Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest OCUL news
Yesterday
5:10am ET
Analysts Offer Insights on Healthcare Companies: Walgreens Boots Alliance (WBA), Ocular Therapeutix (OCUL) and Elevance Health (ELV)
Apr 16
7:13am ET
Ocular Therapeutix announces appointments of CMO, CDO
Apr 16
12:30am ET
Analysts Are Bullish on Top Healthcare Stocks: OptimizeRx (OPRX), Ocular Therapeutix (OCUL)
Apr 15
7:04am ET
Ocular Therapeutix appoints Dugel as President, CEO
Apr 08
6:37am ET
Ocular Therapeutix (OCUL) Gets a Buy from Piper Sandler
Apr 08
6:30am ET
Analysts Offer Insights on Healthcare Companies: Ocular Therapeutix (OCUL), Marinus (MRNS) and Halozyme (HALO)
Apr 07
6:15pm ET
Buy Rating Affirmed: Paxtrava’s Promising Efficacy and Safety Profile in Glaucoma Treatment
Apr 07
6:29am ET
Ocular Therapeutix announces Phase 2 PAXTRAVA glaucoma data
Mar 25
4:43pm ET
Ocular Therapeutix files to sell 43.22M shares of common stock for holders
Mar 13
6:16am ET
Buy Rating Affirmed for Ocular Therapeutix on Robust Revenue Growth and Clinical Trial Prospects
Mar 13
6:10am ET
Ocular Therapeutix price target raised to $15 from $12 at H.C. Wainwright
Mar 13
2:30am ET
Analysts Offer Insights on Healthcare Companies: Ocular Therapeutix (OCUL), Adaptimmune Therapeutics (ADAP) and Arcutis Biotherapeutics (ARQT)
Mar 12
7:25am ET
Ocular Therapeutix price target raised to $11 from $8 at TD Cowen
Mar 12
6:18am ET
Ocular Therapeutix price target raised to $24 from $12 at JMP Securities
Mar 12
5:20am ET
Buy Rating Affirmed for Ocular Therapeutix on Strong Financials and Promising Pipeline Developments
Mar 12
12:35am ET
Buy Rating Affirmed for Ocular Therapeutix on Strong Phase 3 Results and Strategic Focus
Mar 11
7:35pm ET
Balanced Outlook: Hold Rating on Ocular Therapeutix Amidst Trial Progress and Management Changes
Mar 11
4:23pm ET
Ocular Therapeutix reports Q4 EPS (35c), consensus (30c)
Mar 11
2:04pm ET
Ocular Therapeutix options imply 11.5% move in share price post-earnings
Mar 11
8:05am ET
Options Volatility and Implied Earnings Moves Today, March 11, 2024
Mar 04
2:04pm ET
Ocular Therapeutix options imply 8.8% move in share price post-earnings
Feb 26
7:35am ET
Ocular Therapeutix price target raised to $15 from $10 at Piper Sandler
Feb 25
11:37pm ET
Ocular Therapeutix Poised for Growth with Strategic Leadership Hires and Strong Financial Position
Feb 23
5:19am ET
Strategic Leadership and Strong Financials Bolster Buy Rating for Ocular Therapeutix
Feb 22
7:54am ET
Ocular Therapeutix Raises $325M in Strategic Equity Financing
Feb 22
7:52am ET
Ocular Therapeutix reports inducement grants under Nasdaq listing rule
Feb 22
7:49am ET
Ocular Therapeutix announces board of directors, leadership changes
Feb 22
7:46am ET
Ocular Therapeutix sells 32.4M shares at $7.52 in private placement
Feb 15
8:06am ET
Ocular Therapeutix appoints Meyers to Chief Commercial Officer
Feb 13
9:35am ET
Buy Recommendation for Ocular Therapeutix on Positive SOL Trial Amendments and Strong Pipeline Positioning
Feb 12
11:09am ET
Biotech Alert: Searches spiking for these stocks today
No recent press releases are available for OCUL
OCUL Financials
Key terms
Ad Feedback
OCUL Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
OCUL Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
